Verrica Pharmaceuticals Inc (NASDAQ:VRCA) – Investment analysts at Jefferies Financial Group reduced their Q3 2018 EPS estimates for shares of Verrica Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 8th. Jefferies Financial Group analyst D. Steinberg now anticipates that the company will post earnings per share of ($0.24) for the quarter, down from their previous estimate of ($0.20). Jefferies Financial Group currently has a “Buy” rating and a $24.00 price target on the stock. Jefferies Financial Group also issued estimates for Verrica Pharmaceuticals’ Q4 2018 earnings at ($0.28) EPS, FY2018 earnings at ($1.33) EPS, FY2019 earnings at ($0.92) EPS, FY2020 earnings at ($2.31) EPS, FY2021 earnings at ($1.78) EPS and FY2022 earnings at ($0.94) EPS.
Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, August 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.76).
Shares of Verrica Pharmaceuticals opened at $15.10 on Monday, according to Marketbeat. Verrica Pharmaceuticals has a 52-week low of $13.23 and a 52-week high of $23.29.
Several hedge funds have recently bought and sold shares of the company. FMR LLC acquired a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at approximately $21,703,000. Asymmetry Capital Management L.P. acquired a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at approximately $1,184,000. Dean Capital Investments Management LLC acquired a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at approximately $676,000. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at approximately $2,905,000. Finally, Capital Investment Advisory Services LLC acquired a new stake in shares of Verrica Pharmaceuticals in the second quarter valued at approximately $211,000. 1.12% of the stock is owned by institutional investors and hedge funds.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals, Inc operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris.
Featured Story: Stock Symbol
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.